Monday, March 19, 2018 1:36:32 PM
By Christopher Rowland GLOBE STAFF MARCH 19, 2018
In recent years brand-name drug makers realized they could block generic competition by refusing to sell samples of their products to companies that wanted to make the lower-cost copies. All they had to do was cite safety rules that restrict sales of certain drugs with dangerous side effects.
“If they say no, we can’t move forward,’’ said Bruce A. Leicher, senior vice president and general counsel at Momenta Pharmaceuticals, a Cambridge company that is developing “biosimilars,’’ which are generic copies of costly biotechnolgy drugs. “It’s a perfect way to block development of competitive, affordable products.’’
Read more:
https://www.bostonglobe.com/news/nation/2018/03/19/congress-won-stop-drug-companies-who-use-shenanigans-block-generics/SOnAziaeVLhIvGvyX5BYkN/story.html
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM